
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*

KIORA PHARMACEUTICALS, INC.

(Name of Issuer)

COMMON STOCK, PAR VALUE \$0.01 PER SHARE

(Title of Class of Securities)

49721T101

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Page 1 of 12 Pages)

SCHEDULE 13G

CUSIP NO. 49721T101

Page 2 of 12

1		NAMES OF REPORTING PERSONS
		Lincoln Park Capital Fund, LLC
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
		(a) <input type="checkbox"/>
		(b) <input type="checkbox"/>
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION
		Illinois
5		SOLE VOTING POWER
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	0	
	6	SHARED VOTING POWER
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾	
	7	SOLE DISPOSITIVE POWER
	0	
	8	SHARED DISPOSITIVE POWER
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾	
9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
		768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/>
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
		9.99% ⁽³⁾ /9.99% ⁽⁴⁾
12		TYPE OF REPORTING PERSON
		OO

1. Represents reporting person's beneficial ownership of Common Stock as of December 31, 2023.

2. Represents reporting person's beneficial ownership of Common Stock as of February 9, 2024.

3. Represents reporting person's percent of beneficial ownership of Common Stock outstanding as of December 31, 2023. As of December 31, 2023, the reporting person has rights, under the shares of Series F Convertible Preferred Stock of the Issuer (the "Series F") and under five warrants, to acquire an aggregate number of shares of the Issuer's Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer's Common Stock that the reporting person may own, when combined with the 130,139 shares of Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%. Thus, as of December 31, 2023, the number of shares of the Issuer's Common Stock beneficially owned by the reporting person was 768,155 shares, which is 9.99% of the 7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023.

4. Represents Reporting person's percent of beneficial ownership of Common Stock outstanding as of February 9, 2024. As of February 9, 2024, reporting person has rights, under the shares of Series F and under seven warrants, to acquire an aggregate number of shares of the Issuer's Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer's Common Stock that the reporting person may own, when combined with the 17,500 shares of Common Stock and 900,000 shares of restricted Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%. Thus, as of February 9, 2024, the number of shares of the Issuer's Common Stock that the reporting person may own was 2,346,575 shares, which is 9.99% of the 23,489,240 shares outstanding, which was calculated by adding the 7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023, and the 15,800,000 shares of Common Stock issued in a private placement dated January 31, 2024, as provided by the Issuer on a Form 8-K filed with the Securities Exchange Commission on February 1, 2024.

SCHEDULE 13G

CUSIP NO. 49721T101

Page 3 of 12

1	NAMES OF REPORTING PERSONS
	Lincoln Park Capital, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input type="checkbox"/>
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Illinois
	5 SOLE VOTING POWER
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	0
	6 SHARED VOTING POWER
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
	7 SOLE DISPOSITIVE POWER
	0
	8 SHARED DISPOSITIVE POWER
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/>
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	9.99% ⁽³⁾ /9.99% ⁽⁴⁾
12	TYPE OF REPORTING PERSON
	OO

1. Represents reporting person's beneficial ownership of Common Stock as of December 31, 2023.

2. Represents reporting person's beneficial ownership of Common Stock as of February 9, 2024.

3. Represents reporting person's percent of beneficial ownership of Common Stock outstanding as of December 31, 2023. As of December 31, 2023, reporting person has rights, under the shares of Series F and under five warrants, to acquire an aggregate number of shares of the Issuer's Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer's Common Stock that the reporting person may own, when combined with the 130,139 shares of Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%. Thus, as of December 31, 2023, the number of shares of the Issuer's Common Stock beneficially owned by the reporting person was 768,155 shares, which is 9.99% of the 7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023.

4. Represents reporting person's percent of beneficial ownership of Common Stock outstanding as of February 9, 2024. As of February 9, 2024, reporting person has rights, under the shares of Series F and under seven warrants, to acquire an aggregate number of shares of the Issuer's Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer's Common Stock that the reporting person may own, when combined with the 17,500 shares of Common Stock and 900,000 shares of restricted Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%. Thus, as of February 9, 2024, the number of shares of the Issuer's Common Stock that the reporting person may own was 2,346,575 shares, which is 9.99% of the 23,489,240 shares outstanding, which was calculated by adding the 7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023, and the 15,800,000 shares of Common Stock issued in a private placement dated January 31, 2024, as provided by the Issuer on a Form 8-K filed with the Securities Exchange Commission on February 1, 2024.

SCHEDULE 13G

CUSIP NO. 49721T101

Page 4 of 12

1	NAMES OF REPORTING PERSONS
	Rockledge Capital Corporation
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input type="checkbox"/>
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Texas
	5 SOLE VOTING POWER
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	0
	6 SHARED VOTING POWER
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
	7 SOLE DISPOSITIVE POWER
	0
	8 SHARED DISPOSITIVE POWER
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/>
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	9.99% ⁽³⁾ /9.99% ⁽⁴⁾
12	TYPE OF REPORTING PERSON
	CO

1. Represents reporting person's beneficial ownership of Common Stock as of December 31, 2023.

2. Represents reporting person's beneficial ownership of Common Stock as of February 9, 2024.

3. Represents reporting person's percent of beneficial ownership of Common Stock outstanding as of December 31, 2023. As of December 31, 2023, reporting person has rights, under the shares of Series F and under five warrants, to acquire an aggregate number of shares of the Issuer's Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer's Common Stock that the reporting person may own, when combined with the 130,139 shares of Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%. Thus, as of December 31, 2023, the number of shares of the Issuer's Common Stock beneficially owned by the reporting person was 768,155 shares, which is 9.99% of the 7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023.

4. Represents reporting person's percent of beneficial ownership of Common Stock outstanding as of February 9, 2024. As of February 9, 2024, reporting person has rights, under the shares of Series F and under seven warrants, to acquire an aggregate number of shares of the Issuer's Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer's Common Stock that the reporting person may own, when combined with the 17,500 shares of Common Stock and 900,000 shares of restricted Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%. Thus, as of February 9, 2024, the number of shares of the Issuer's Common Stock that the reporting person may own was 2,346,575 shares, which is 9.99% of the 23,489,240 shares outstanding, which was calculated by adding the 7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023, and the 15,800,000 shares of Common Stock issued in a private placement dated January 31, 2024, as provided by the Issuer on a Form 8-K filed with the Securities Exchange Commission on February 1, 2024.

SCHEDULE 13G

CUSIP NO. 49721T101

Page 5 of 12

1	NAMES OF REPORTING PERSONS
	Joshua B. Scheinfeld
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input type="checkbox"/>
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	United States
	5 SOLE VOTING POWER
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	0
	6 SHARED VOTING POWER
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
	7 SOLE DISPOSITIVE POWER
	0
	8 SHARED DISPOSITIVE POWER
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/>
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	9.99% ⁽³⁾ /9.99% ⁽⁴⁾
12	TYPE OF REPORTING PERSON
	IN

1. Represents reporting person's beneficial ownership of Common Stock as of December 31, 2023.

2. Represents reporting person's beneficial ownership of Common Stock as of February 9, 2024.

3. Represents reporting person's percent of beneficial ownership of Common Stock outstanding as of December 31, 2023. As of December 31, 2023, reporting person has rights, under the shares of Series F and under five warrants, to acquire an aggregate number of shares of the Issuer's Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer's Common Stock that the reporting person may own, when combined with the 130,139 shares of Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%. Thus, as of December 31, 2023, the number of shares of the Issuer's Common Stock beneficially owned by the reporting person was 768,155 shares, which is 9.99% of the 7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023.

4. Represents reporting person's percent of beneficial ownership of Common Stock outstanding as of February 9, 2024. As of February 9, 2024, reporting person has rights, under the shares of Series F and under seven warrants, to acquire an aggregate number of shares of the Issuer's Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer's Common Stock that the reporting person may own, when combined with the 17,500 shares of Common Stock and 900,000 shares of restricted Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%. Thus, as of February 9, 2024, the number of shares of the Issuer's Common Stock that the reporting person may own was 2,346,575 shares, which is 9.99% of the 23,489,240 shares outstanding, which was calculated by adding the 7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023, and the 15,800,000 shares of Common Stock issued in a private placement dated January 31, 2024, as provided by the Issuer on a Form 8-K filed with the Securities Exchange Commission on February 1, 2024.

SCHEDULE 13G

CUSIP NO. 49721T101

Page 6 of 12

1	NAMES OF REPORTING PERSONS
	Alex Noah Investors, Inc.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input type="checkbox"/>
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Illinois
	5 SOLE VOTING POWER
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	0
	6 SHARED VOTING POWER
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
	7 SOLE DISPOSITIVE POWER
	0
	8 SHARED DISPOSITIVE POWER
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/>
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	9.99% ⁽³⁾ /9.99% ⁽⁴⁾
12	TYPE OF REPORTING PERSON
	CO

1. Represents reporting person's beneficial ownership of Common Stock as of December 31, 2023.

2. Represents reporting person's beneficial ownership of Common Stock as of February 9, 2024.

3. Represents reporting person's percent of beneficial ownership of Common Stock outstanding as of December 31, 2023. As of December 31, 2023, reporting person has rights, under the shares of Series F and under five warrants, to acquire an aggregate number of shares of the Issuer's Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer's Common Stock that the reporting person may own, when combined with the 130,139 shares of Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%. Thus, as of December 31, 2023, the number of shares of the Issuer's Common Stock beneficially owned by the reporting person was 768,155 shares, which is 9.99% of the 7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023.

4. Represents reporting person's percent of beneficial ownership of Common Stock outstanding as of February 9, 2024. As of February 9, 2024, reporting person has rights, under the shares of Series F and under seven warrants, to acquire an aggregate number of shares of the Issuer's Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer's Common Stock that the reporting person may own, when combined with the 17,500 shares of Common Stock and 900,000 shares of restricted Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%. Thus, as of February 9, 2024, the number of shares of the Issuer's Common Stock that the reporting person may own was 2,346,575 shares, which is 9.99% of the 23,489,240 shares outstanding, which was calculated by adding the 7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023, and the 15,800,000 shares of Common Stock issued in a private placement dated January 31, 2024, as provided by the Issuer on a Form 8-K filed with the Securities Exchange Commission on February 1, 2024.

SCHEDULE 13G

CUSIP NO. 49721T101

Page 7 of 12

1	NAMES OF REPORTING PERSONS
	Jonathan I. Cope
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input type="checkbox"/>
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	United States
	5 SOLE VOTING POWER
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	0
	6 SHARED VOTING POWER
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
	7 SOLE DISPOSITIVE POWER
	0
	8 SHARED DISPOSITIVE POWER
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/>
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	9.99% ⁽³⁾ /9.99% ⁽⁴⁾
12	TYPE OF REPORTING PERSON
	IN

1. Represents reporting person's beneficial ownership of Common Stock as of December 31, 2023.

2. Represents reporting person's beneficial ownership of Common Stock as of February 9, 2024.

3. Represents reporting person's percent of beneficial ownership of Common Stock outstanding as of December 31, 2023. As of December 31, 2023, reporting person has rights, under the shares of Series F and under five warrants, to acquire an aggregate number of shares of the Issuer's Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer's Common Stock that the reporting person may own, when combined with the 130,139 shares of Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%. Thus, as of December 31, 2023, the number of shares of the Issuer's Common Stock beneficially owned by the reporting person was 768,155 shares, which is 9.99% of the 7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023.

4. Represents reporting person's percent of beneficial ownership of Common Stock outstanding as of February 9, 2024. As of February 9, 2024, reporting person has rights, under the shares of Series F and under seven warrants, to acquire an aggregate number of shares of the Issuer's Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer's Common Stock that the reporting person may own, when combined with the 17,500 shares of Common Stock and 900,000 shares of restricted Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%. Thus, as of February 9, 2024, the number of shares of the Issuer's Common Stock that the reporting person may own was 2,346,575 shares, which is 9.99% of the 23,489,240 shares outstanding, which was calculated by adding the 7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023, and the 15,800,000 shares of Common Stock issued in a private placement dated January 31, 2024, as provided by the Issuer on a Form 8-K filed with the Securities Exchange Commission on February 1, 2024.

Item 1.**(a) Name of Issuer:**

Kiora Pharmaceuticals, Inc., a Delaware corporation (the "Issuer")

(b) Address of Issuer's Principal Executive Offices:

332 Encinitas Blvd., Suite 102, Encinitas, CA 92024

Item 2.**(a) Name of Person Filing:**

Lincoln Park Capital Fund, LLC ("LPC Fund")

Lincoln Park Capital, LLC ("LPC")

Rockledge Capital Corporation ("RCC")

Joshua B. Scheinfeld ("Mr. Scheinfeld")

Alex Noah Investors, Inc. ("Alex Noah")

Jonathan I. Cope ("Mr. Cope") and, collectively with LPC Fund, LPC, RCC, Mr. Scheinfeld and Alex Noah, the "Reporting Persons")

(b) Address of Principal Business Office, or if None, Residence:

The address of the principal business office of each of the Reporting Persons is:

440 North Wells, Suite 410

Chicago, Illinois 60654

(c) Citizenship:

LPC Fund is an Illinois limited liability company

LPC is an Illinois limited liability company

RCC is a Texas corporation

Mr. Scheinfeld is a United States citizen

Alex Noah is an Illinois corporation

Mr. Cope is a United States citizen

SCHEDULE 13G

CUSIP NO. 49721T101

Page 9 of 12

(d) Title of Class of Securities:

Common Stock, Par Value \$0.01 Per Share ("Common Stock")

(e) CUSIP Number:

49721T101

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
- (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
- (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _____

Item 4. Ownership.

Reporting person	Amount beneficially owned:	Percent of class:	Sole power to vote or direct the vote:	Shared power to vote or to direct the vote:	Sole power to dispose or to direct the disposition of:	Shared power to dispose or to direct the disposition of:
Lincoln Park Capital Fund, LLC	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾	9.99%	0	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾	0	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
Lincoln Park Capital, LLC	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾	9.99%	0	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾	0	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
Rockledge Capital Corporation	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾	9.99%	0	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾	0	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
Joshua B. Scheinfeld	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾	9.99%	0	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾	0	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
Alex Noah Investors, Inc.	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾	9.99%	0	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾	0	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾
Jonathan I. Cope	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾	9.99%	0	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾	0	768,155 ⁽¹⁾ /2,346,575 ⁽²⁾

1. As of December 31, 2023, LPC Fund owned the following securities of the Issuer: (i) 130,139 shares of outstanding Common Stock; (ii) warrants to purchase 828,919 shares of Common Stock currently exercisable at \$0.5231 per share that expire on June 6, 2026, subject to a 9.99% beneficial ownership cap (the "Series C Warrants"); (iii) warrants to purchase 828,919 shares of Common Stock currently exercisable at \$0.5231 per share that expire on June 6, 2024, subject to a 9.99% beneficial ownership cap, (the "Series D Warrants"); (iv) warrants to purchase 105,596 shares of Common Stock currently exercisable at \$3.538 that expire on August 3, 2028, subject to a 9.99% beneficial ownership cap, pursuant to a securities purchase agreement dated February 2, 2023 (the "2023 SPA Warrants"); (v) warrants to purchase 121,875 shares of Common Stock currently exercisable at \$5.97 per share that expire on November 22, 2024, subject to a 9.99% beneficial ownership cap, pursuant to a private placement on or about November 22, 2022 (the "2022 PP Warrants"); (vi) warrants to purchase 121,875 shares of Common Stock currently exercisable at \$8.00 per share that expire on July 22, 2027, subject to a 9.99% beneficial ownership cap (the "Additional Warrants"); and (vii) 570 shares of Series F that are convertible into 381,780 shares of Common Stock, subject to a 9.99% beneficial ownership cap.

Based on the information provided on Issuer's Form 10-Q, filed with the Securities Exchange Commission on November 9, 2023, there were 7,689,240 shares of Common Stock Outstanding. Accordingly, as of December 31, 2023, LPC Fund directly beneficially owned an aggregate of 768,155 shares of Common Stock, representing the 130,139 shares of Common Stock presently owned combined with number of shares of Common Stock that may be acquired by LPC Fund as of December 31, 2023 under the above warrants and Series F without exceeding the 9.99% beneficial ownership limitation on the exercise of the Warrants, or the 9.99% beneficial ownership limitation on the conversion of the Series F.

2. As of February 9, 2024, LPC Fund owned the following securities of the Issuer: (i) 17,500 shares of outstanding Common Stock; (ii) warrants to purchase 818,236 shares of Common Stock currently exercisable at a price of \$0.6076 per share, which expires on the earlier date of: (a) February 5, 2029 and (b) 30 days after the Company announces topline data from a Phase 2 clinical trial (ABACUS-2) of KIO-301 in retinitis pigmentosa and, following such announcement, the daily volume weighted average price of the Issuer's common stock equals or exceeds \$1.1048 for 30 consecutive trading days (pursuant to Issuer's Form 8-K, filed with the Securities Exchange Commission on February 1, 2024); (iii) warrants to purchase 818,236 shares of Common Stock currently exercisable at a price of \$0.6076 per share, which expires on the earlier date of: (a) February 5, 2029 and (b) 30 days after the Company announces topline data from a Phase 2 clinical trial of KIO-104 for treatment in posterior non-infectious uveitis and, following such announcement, the daily volume weighted average price of the Issuer's common stock equals or exceeds \$1.3810 for 30 consecutive trading days (pursuant to Issuer's Form 8-K, filed with the Securities Exchange Commission on February 1, 2024); (iv) Series C Warrants to purchase up to 828,919 shares of Common Stock; (v) Series D Warrants to purchase 578,919 shares of Common Stock; (vi) 2023 SPA Warrants to purchase up to 105,596 shares of Common Stock; (vii) 2022 PP Warrants to purchase up to 121,875 shares of Common Stock; (viii) 750 shares of Series F that are convertible into 381,780 shares of Common Stock; (ix) Additional Warrants to purchase up to 121,875 shares of Common stock; and (ix) 900,000 shares of restricted Common Stock

Pursuant to §240.13d-1, which states that "any person, in determining the amount of outstanding securities of a class of equity securities, may rely upon information set forth in the issuer's most recent quarterly or annual report, and any current report subsequent thereto, filed with the Commission pursuant to this Act, unless he knows or has reason to believe that information contained therein is inaccurate," the Reporting Persons are including updated information in connection with the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 1, 2024 (the "Current Report"). Based on the information provided in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities Exchange Commission on November 9, 2023, where the Issuer disclosed that there were 7,689,240 shares of Common Stock outstanding, and in the Current Report, where 15,800,000 shares of Common Stock were issued in a private placement on or about January 31, 2024, the total Common Stock outstanding was 23,489,240 shares. Accordingly, as of February 9, 2024, LPC Fund directly beneficially owned an aggregate of 2,347,575 shares of Common Stock, representing the 17,500 shares of Common Stock presently owned and the 900,000 shares of restricted Common Stock currently owned, combined with number of shares of Common Stock that may be acquired by LPC Fund as of February 9, 2024 under the above warrants and Series F without exceeding the 9.99% beneficial ownership limitation on the exercise of the warrants, or the 9.99% beneficial ownership limitation on the conversion of the Series F.

LPC is the Managing Member of LPC Fund. RCC and Alex Noah are the Managing Members of LPC. Mr. Scheinfeld is the president and sole shareholder of RCC, as well as a principal of LPC. Mr. Cope is the president and sole shareholder of Alex Noah, as well as a principal of LPC. As a result of the foregoing, Mr. Scheinfeld and Mr. Cope have shared voting and shared investment power over the shares of Common Stock of the Issuer held directly by LPC Fund.

Pursuant to Section 13(d) of the Act and the rules thereunder, each of LPC, RCC, Mr. Scheinfeld, Alex Noah, and Mr. Cope may be deemed to be a beneficial owner of the shares of Common Stock of the Issuer beneficially owned directly by LPC Fund.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Pursuant to Rule 13d-4 of the Act, each of LPC, RCC, Mr. Scheinfeld, Alex Noah, and Mr. Cope disclaims beneficial ownership of the shares of Common Stock of the Issuer held directly by LPC Fund.

SCHEDULE 13G

CUSIP NO. 49721T101

Page 11 of 12

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2024

LINCOLN PARK CAPITAL FUND, LLC

LINCOLN PARK CAPITAL, LLC

BY:LINCOLN PARK CAPITAL, LLC

BY: ROCKLEDGE CAPITAL CORPORATION

BY:ROCKLEDGE CAPITAL CORPORATION

By: /s/ Joshua B. Scheinfeld
Name: Joshua B. Scheinfeld
Title: President

By: /s/ Joshua B. Scheinfeld
Name: Joshua B. Scheinfeld
Title: President

LINCOLN PARK CAPITAL FUND, LLC

LINCOLN PARK CAPITAL, LLC

BY:LINCOLN PARK CAPITAL, LLC

BY: ALEX NOAH INVESTORS, INC.

BY:ALEX NOAH INVESTORS, INC.

By: /s/ Jonathan I. Cope
Name: Jonathan I. Cope
Title: President

By: /s/ Jonathan I. Cope
Name: Jonathan I. Cope
Title: President

ROCKLEDGE CAPITAL CORPORATION

ALEX NOAH INVESTORS, INC.

By: /s/ Joshua B. Scheinfeld
Name: Joshua B. Scheinfeld
Title: President

By: /s/ Jonathan I. Cope
Name: Jonathan I. Cope
Title: President

JOSHUA B. SCHEINFELD

JONATHAN I. COPE

By: /s/ Joshua B. Scheinfeld
Name: Joshua B. Scheinfeld
Title: President

By: /s/ Jonathan I. Cope
Name: Jonathan I. Cope
Title: President

LIST OF EXHIBITS

<u>Exhibit No.</u>	<u>Description</u>
1	Joint Filing Agreement

Joint Filing Agreement

The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

In accordance with Rule 13d-1(k)(1) promulgated under the Securities and Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such Schedule 13G with respect to the Common Stock of the Issuer, beneficially owned by each of them. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13G.

[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned hereby execute this Agreement as of February 14, 2023.

LINCOLN PARK CAPITAL FUND, LLC

LINCOLN PARK CAPITAL, LLC

BY:LINCOLN PARK CAPITAL, LLC

BY: ROCKLEDGE CAPITAL CORPORATION

BY:ROCKLEDGE CAPITAL CORPORATION

By: /s/ Joshua B. Scheinfeld
Name: Joshua B. Scheinfeld
Title: President

By: /s/ Joshua B. Scheinfeld
Name: Joshua B. Scheinfeld
Title: President

LINCOLN PARK CAPITAL FUND, LLC

LINCOLN PARK CAPITAL, LLC

BY:LINCOLN PARK CAPITAL, LLC

BY: ALEX NOAH INVESTORS, INC.

BY:ALEX NOAH INVESTORS, INC.

By: /s/ Jonathan I. Cope
Name: Jonathan I. Cope
Title: President

By: /s/ Jonathan I. Cope
Name: Jonathan I. Cope
Title: President

ROCKLEDGE CAPITAL CORPORATION

ALEX NOAH INVESTORS, INC.

By: /s/ Joshua B. Scheinfeld
Name: Joshua B. Scheinfeld
Title: President

By: /s/ Jonathan I. Cope
Name: Jonathan I. Cope
Title: President

JOSHUA B. SCHEINFELD

JONATHAN I. COPE

By: /s/ Joshua B. Scheinfeld
Name: Joshua B. Scheinfeld
Title: President

By: /s/ Jonathan I. Cope
Name: Jonathan I. Cope
Title: President
